Last Updated : January 28, 2025
Details
FilesGeneric Name:
durvalumab, carboplatin, paclitaxel
Project Status:
Active
Therapeutic Area:
Endometrial cancer that is mismatch repair deficient (dMMR)
Manufacturer:
AstraZeneca Canada Inc.
Call for patient/clinician input open:
Brand Name:
Imfinzi
Project Line:
Reimbursement Review
Project Number:
PC0366-000
Call for patient/clinician input closed:
Tumour Type:
Gynecology
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Imfinzi in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adult patients with primary advanced or recurrent mismatch repair deficient (dMMR) endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with Imfinzi as monotherapy.
Submission Type:
Initial
Companion Diagnostics:
Yes
Fee Schedule:
Schedule A
Indications:
Imfinzi in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adult patients with primary advanced or recurrent mismatch repair deficient (dMMR) endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with Imfinzi as monotherapy.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | 04-Sep-24 |
|---|---|
| Call for patient/clinician input closed | 28-Oct-24 |
| Submission received | 16-Oct-24 |
| Submission accepted | 30-Oct-24 |
| Review initiated | 31-Oct-24 |
| Draft CADTH review report(s) provided to sponsor for comment | 22-Jan-25 |
| Deadline for sponsors comments | 03-Feb-25 |
| CADTH review report(s) and responses to comments provided to sponsor | 28-Feb-25 |
| Expert committee meeting (initial) | 12-Mar-25 |
| Draft recommendation issued to sponsor | March 25, 2025 To March 27, 2025 |
| Draft recommendation posted for stakeholder feedback | 03-Apr-25 |
| End of feedback period | 17-Apr-25 |
Files
Last Updated : January 28, 2025